Determining the critical micelle concentration of a novel lipid-lowering agent, disodium ascorbyl phytostanyl phosphate (FM-VP4), using a fluorescence depolarization procedure

Confocal Raman spectroscopy at different laser wavelengths in analyzing stratum corneum and skin penetration properties of mixed PEGylated emulsifier systems

Emulsifier mixtures are widely used in cosmetics and pharmaceutics and thus, brought extensive studies for their performances on skin applications. PEG-20cetyl ether (C20) is recently proposed to induce skin irritation and is of interest to study its skin interactions when mixed with other emulsifiers. PEG-2oleyl ether (O2) and PEG-20stearyl ether (S20) are selected and in specific, 50 mM of C20, O2, S20 as well as Mix1 (50 mM C20 mixed with 50 mM O2) and Mix2 (50 mM C20 mixed with 50 mM S20) solutions were applied on skin samples. Confocal Raman spectroscopy (CRS) analyses of stratum corneum (SC) thickness and SC lipid content were performed after 4 h skin treatments. In parallel, skin penetration properties were also evaluated via CRS by applying procaine solutions with/without emulsifiers on skin samples for 24 h. In terms of the CRS measurements, two excitation wavelengths of 532 nm and 785 nm are both utilized in this study and we secondly aimed to compare their results and suitability in SC and skin analyses. Based on the experimental observations, comparable results are obtained by using both excitation wavelengths of 532 nm and 785 nm demonstrating their suitability in analyzing SC and skin samples. Thereinto, 785 nm laser wavelength shows the advantage of deeper skin penetration and allows the measurements of fluorescent skin samples; 532 nm laser wavelength enables simple measurement performance without substrate and coverslip interference. With regards to the results of emulsifier mixtures, the addition of S20 and O2 reduced the skin interactions and penetration enhancing ability of C20, giving us the hint to build milder systems with emulsifier mixtures. Besides, the CRS results of stronger skin interruption were also correlated with the higher critical micelle concentration (CMC) values of emulsifiers and their mixtures, which may provide evidence in explaining the interactions between emulsifiers and skin.

Evaluation of the effect of plant sterols on the intestinal processing of cholesterol using an in vitro lipolysis model

An in vitro lipolysis model was utilized to study the effect of stigmastanol (lipophilic phytosterol) and disodium ascorbyl phytostanol phosphate (DAPP) (modified hydrophilic phytostanol) on intestinal processing of cholesterol to gain further understanding of their cholesterol lowering mechanism. Lipolysis results showed that stigmastanol, if given in powder alone, had no effect on cholesterol processing probably due to its poor solubility. Stigmastanol suspension formulation re-distributed cholesterol from aqueous phase to oil and sediment phases. The water soluble DAPP has changed cholesterol distribution even more significantly by transferring cholesterol from aqueous phase to sediment phase. Moreover, the results provided evidence that DAPP inhibited triglyceride digestion in vitro. Considering DAPP as a surfactant with the same lipophilic sterol ring as bile salt, its ability to inhibit triglyceride lipolysis may be due to its competition with bile salt for the substrate surface, thereby hindering the lipolysis of triglyceride and inhibiting cholesterol solubilization with the lipolysis products. It can be speculated that the cholesterol lowering mechanism of DAPP during intestinal digestion is related to its ability to act as a surfactant closely resembling bile salt.

Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia

OBJECTIVE

This study investigated the efficacy, safety, tolerability, and pharmacokinetics of a novel cholesterol absorption inhibitor, FM-VP4, comprising disodium ascorbyl sitostanol phosphate (DASP) and disodium ascorbyl campestanol phosphate (DACP).

METHODS

In phase 1, 30 men received a single dose of 100, 200, 400, 800, 1,600, or 2,000 mg FM-VP4 or placebo. In phase 2, 100 men were treated with 100, 200, 400, or 800 mg/day of FM-VP4 or placebo for 4 weeks.

RESULTS

The drug was well tolerated at each single or multiple dose level. After 4 weeks of treatment, low-density lipoprotein cholesterol (LDL-C) levels changed by 2.7% in the placebo group and by 2.9%, -4.2%, and -4.6% in the 100, 200, and 800 mg/day groups, respectively, which was not statistically significant. However, 400 mg/day of FM-VP4 significantly decreased LDL-C by 6.5% (p=0.02). Phase 1 showed that DACP and DASP were absorbed into plasma with a median t(max) of 12 h for both components, and clearance was slow with a mean t(1/2lambda) of 57 h. During 4 weeks of treatment, steady state was reached by approximately 8 days.

CONCLUSION

This study demonstrated that up to 800 mg/day of FM-VP4 is safe and well tolerated for at least 4 weeks. Furthermore, the higher doses significantly reduced LDL-C by 7% compared with baseline or by 10% compared with placebo, with the maximum effect reached at 400 mg/day.